Sartorius/€SRT3
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Sartorius
Sartorius AG, trading under the ticker symbol SRT3, is a global provider of laboratory and bioprocess technologies, offering products and services that cater to the needs of the biopharmaceutical and research industries. Founded in 1870 and headquartered in Göttingen, Germany, the company specializes in filtration, fermentation, fluid management, and laboratory products, supporting clients ranging from research facilities to large-scale biopharmaceutical manufacturers. Operating internationally, Sartorius is crucial in enabling the development and production of biotech medications and vaccines, solidifying its role as a crucial player in the life sciences and biotechnology sectors.
- Ticker
- €SRT3
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 14,273
- Headquarters
- Göttingen, Germany
- Website
- www.sartorius.com
Sartorius Metrics
BasicAdvanced
€18B
-
-
1.45
€0.74
0.26%
Price and volume
Market cap
€18B
Beta
1.45
52-week high
€290.00
52-week low
€198.00
Average daily volume
124K
Dividend rate
€0.74
Financial strength
Current ratio
1.068
Quick ratio
0.42
Long term debt to equity
0.828
Total debt to equity
0.944
Dividend payout ratio (TTM)
23.25%
Interest coverage (TTM)
4.58%
Profitability
EBITDA (TTM)
978
Gross margin (TTM)
45.43%
Net profit margin (TTM)
5.96%
Operating margin (TTM)
17.80%
Effective tax rate (TTM)
30.46%
Revenue per employee (TTM)
€260,000
Management effectiveness
Return on assets (TTM)
4.23%
Return on equity (TTM)
7.86%
Valuation
Dividend yield (TTM)
0.26%
Forward dividend yield
0.26%
Growth
Revenue change (TTM)
4.19%
3-year revenue growth (CAGR)
0.52%
10-year revenue growth (CAGR)
11.36%
3-year dividend per share growth (CAGR)
-19.90%
10-year dividend per share growth (CAGR)
7.18%
What the Analysts think about Sartorius
Analyst ratings (Buy, Hold, Sell) for Sartorius stock.
Analyst projections of the future price of Sartorius stock.
Bulls say / Bears say
Nine-month operational sales rose 8.1% in constant currencies, while underlying EBITDA margin widened by 0.5 percentage points to 30.2%. That shows the recovery is translating into profitable growth. (Sartorius)
Growth is not relying only on recurring consumables: bioprocess equipment and laboratory instruments also contributed as customer investment recovered. That broadens the sources of sales growth. (Sartorius)
Sartorius raised its Lab Products & Services outlook to the upper end of its 2%–6% growth range and expects a margin slightly above 21%. Strong bioanalytics demand and AI-enabled research tools give the division exposure to expanding drug-discovery workflows. (Sartorius)
Customer compensation linked to US tariff refunds could reduce expected group revenue by up to €40 million versus initial assumptions, putting reported growth in the lower half of guidance. This leaves near-term sales exposed to trade-policy changes. (Sartorius)
Management said some Lab Products & Services demand was pulled forward into the third quarter and cautioned against extrapolating the quarter’s strength. That makes the upgraded lab outlook less certain. (Investing.com)
Net debt was €3.68 billion and leverage stood at 3.3 times underlying EBITDA after nine months; management expects it to remain slightly above 3 times at year-end. Leverage is improving, but remains material and makes continued cash generation important. (Sartorius, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
Sartorius Financial Performance
Revenues and expenses
Sartorius Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Sartorius
AllEURUSD
Fund name | Fund size | €SRT3 weighting |
|---|---|---|
iShares TecDAX€EXS2 | €645M | 5.53% |
iShares MDAX€EXS3 | €1.5B | 4.98% |
iShares MDAX€EXID | €34M | 4.98% |
iShares EURO STOXX Mid€DJMC | €595M | 0.91% |
iShares EURO STOXX Mid Cap£DJMC | €595M | 0.91% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.